aspirin

Observational studies have associated use of aspirin and selective cyclooxygenase inhibitors with decreased recurrence and improved survival in patients with colon cancer...This was a post hoc analysis of the phase 3 Cancer and Leukemia Group B (now Alliance)/Southwest Oncology Group 80702 randomized clinical trial (2010-2015) assessing adjuvant celecoxib vs placebo and 3 vs 6 months of adjuvant 5-fluorouracil, leucovorin, and oxaliplatin for stage III colon cancer...The findings of this post hoc analysis suggest that ctDNA status has the potential to inform clinical decision-making among patients with stage III colon cancer who should consider adjuvant celecoxib in addition to conventional chemotherapy. ClinicalTrials.gov Identifier: NCT01150045.

P3, N=2570, Not yet recruiting, Montreal Heart Institute

P=N/A, N=130, Completed, Thomas Jefferson University | Active, not recruiting --> Completed

In the xenograft model, the combination treatment suppressed tumor growth by approximately 70%, an effect comparable to paclitaxel (PTX). In contrast to PTX, the combination of rhAPE1/Ref-1 and ASA did not cause hematological toxicity, such as anemia or thrombocytopenia. The combination of rhAPE1/Ref-1 and ASA represents a promising new therapeutic strategy for TNBC by enhancing apoptosis and significantly inhibiting tumor progression in a mouse xenograft model.

Treatment regimens comprised lenalidomide (n = 36) or thalidomide (n = 15) with daratumumab, and pomalidomide (n = 2) with isatuximab. Most patients (n = 38) received frontline therapy, and all were given thromboprophylaxis according to guidelines, mainly aspirin (73%)...Given the limited number of patients and thrombotic events, and the cytokine data available for only two VTE cases, these associations should be regarded as exploratory and interpreted with caution. Overall, these exploratory findings warrant validation in larger, independent cohorts and may help generate hypotheses on how inflammatory signatures influence thrombotic risk and prophylaxis efficacy in MM patients receiving IMiD/anti-CD38-based regimens.

P4, N=18883, Completed, Dartmouth-Hitchcock Medical Center | Active, not recruiting --> Completed

P3, N=5676, Not yet recruiting, Christian Medical College and Hospital, Ludhiana, India

P1, N=10, Active, not recruiting, USDA, Western Human Nutrition Research Center | Trial completion date: Sep 2025 --> Sep 2026

Notable medications include RANKL inhibitors, which boost immune cell responses; TGF-β inhibitors, which improve T cell infiltration; and metformin, which activates cytotoxic T lymphocytes...On the other hand, aspirin may enhance immune checkpoint inhibitors by blocking the immunological milieu that tumors produce...Future developments in personalized medicine and artificial intelligence may increase the efficacy of drug repurposing in cancer treatment. To fully realize the potential of repurposed medications in enhancing the results for cancer patients, interdisciplinary cooperation between the academic community, business leaders, and regulatory bodies will be required.

P3, N=100, Not yet recruiting, McMaster University

P2, N=40, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Nov 2025 --> Nov 2026 | Trial primary completion date: Nov 2025 --> Nov 2026

A low-dose combination therapy of fostamatinib, Aducanumab, and acetylsalicylic acid (aspirin) may control TEP effects. In conclusion, our preclinical in silico approach revealed FDA-approved drugs that allow therapeutic targeting of metastasis-promoting TEPs and target NSCLC at the same time.